Citadel Advisors
ALDX icon

Citadel Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Citadel Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Sell
123,900
-107,300
-46% -$470K ﹤0.01% 11327
2025
Q4 		$1.2M Buy
231,200
+53,500
+30% +$275K ﹤0.01% 6999
2025
Q3 		$928K Buy
177,700
+63,900
+56% +$333K ﹤0.01% 7693
2025
Q2 		$436K Buy
113,800
+34,300
+43% +$88.7K ﹤0.01% 8952
2025
Q1 		$457K Sell
79,500
-5,100
-6% -$30.1K ﹤0.01% 8672
2024
Q4 		$422K Sell
84,600
-7,100
-8% -$36.4K ﹤0.01% 8935
2024
Q3 		$494K Buy
91,700
+3,600
+4% +$17.1K ﹤0.01% 8283
2024
Q2 		$292K Buy
88,100
+4,100
+5% +$16.1K ﹤0.01% 9200
2024
Q1 		$275K Buy
84,000
+61,900
+280% +$204K ﹤0.01% 9655
2023
Q4 		$77.6K Buy
22,100
+13,600
+160% +$42K ﹤0.01% 11263
2023
Q3 		$56.8K Sell
8,500
-21,600
-72% -$160K ﹤0.01% 11603
2023
Q2 		$253K Sell
30,100
-49,600
-62% -$489K ﹤0.01% 9387
2023
Q1 		$791K Buy
79,700
+23,100
+41% +$163K ﹤0.01% 7303
2022
Q4 		$394K Sell
56,600
-14,900
-21% -$85.2K ﹤0.01% 8745
2022
Q3 		$382K Buy
+71,500
New +$429K ﹤0.01% 9051
2022
Q1 		– Sell
-69,900
Closed -$280K – 13489
2021
Q4 		$280K Buy
69,900
+1,400
+2% +$10.7K ﹤0.01% 11062
2021
Q3 		$601K Sell
68,500
-1,700
-2% -$15.6K ﹤0.01% 9414
2021
Q2 		$795K Sell
70,200
-11,500
-14% -$138K ﹤0.01% 8959
2021
Q1 		$971K Buy
81,700
+57,700
+240% +$664K ﹤0.01% 8187
2020
Q4 		$165K Buy
24,000
+600
+3% +$4.21K ﹤0.01% 9880
2020
Q3 		$173K Sell
23,400
-2,500
-10% -$16.1K ﹤0.01% 8918
2020
Q2 		$108K Buy
+25,900
New +$94.6K ﹤0.01% 8948
2019
Q3 		– Sell
-39,000
Closed -$234K – 9106
2019
Q2 		$234K Sell
39,000
-35,400
-48% -$266K ﹤0.01% 7959
2019
Q1 		$672K Buy
+74,400
New +$632K ﹤0.01% 6286

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's ALDX Position: Q1 2026 in Review

Citadel Advisors opened a new position in Aldeyra Therapeutics (ALDX) in Q1 2026: 266,340 shares worth $450K. The stake represents ﹤0.01% of the portfolio and ranks #9556 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ALDX as recently as Q3 2025.

Citadel Advisors first reported a position in ALDX in Q1 2018 and has held it in 30 quarters since. The position peaked at $11M in Q1 2022. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Citadel Advisors held 266,340 shares of Aldeyra Therapeutics worth $450K as of Q1 2026.
  • Aldeyra Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Aldeyra Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9556 holding.
  • Citadel Advisors first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 30 quarters since.
  • Citadel Advisors's Aldeyra Therapeutics position peaked at $11M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.